The FDA decision on Lantheus Holdings Inc.’s (LNTH) LNTH-2501 is anticipated on June 29, 2026.LNTH-2501 is a diagnostic kit for the preparation of Ga 68 edotreotide Injection, indicated for use with positron emission tomography (PET) imaging for localization of somatostatin receptor-positive (SSTR+) neuroendocrine tumors (NETs) in adult and pediatric patients.If approved, LNTH-2501 may complement the company’s therapeutic candidate PNT2003 as part of a theranostic approach of delivering integrated diagnostic and therapeutic solutions for patients with cancer.LNTH closed Tuesday’s (June 2, 2026) trading at $96.30, down 0.85%.